Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression

Journal of Alzheimer's Disease

Volumn 32, Issue 1, 2012, Pages 95-100

  Maetzler, Walter ^a,b,c   Langkamp, Markus ^d   Lerche, Stefanie ^a,b   Godau, Jana ^a,b   Brockmann, Kathrin ^a,b   Gaenslen, Alexandra ^a,b   Huber, Heiko ^a,b   Wurster, Isabel ^a,b   Niebler, Raphael ^e   Eschweiler, Gerhard W ^e   Berg, Daniela ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d Mediagnost Inc   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Alzheimer's disease; autoimmune disease; depression; risk factor

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; IMMUNOGLOBULIN G ANTIBODY; PROTEIN S100B;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; HYPOSMIA; LIFETIME DEPRESSION; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL;

EID: 84867487110     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120625     Document Type: Article

References (26)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
2. Byers AL, Yaffe K (2011) Depression and risk of developing dementia. Nat Rev Neurol 7, 323-331.
3. Jorm AF (2001) History of depression as a risk factor for dementia: An updated review. Aust N Z J Psychiatry 35, 776-781.
4. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63, 530-538.
5. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K (2001) The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain Behav Immun 15, 199-226.
6. Maes M,Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, MajM(2009) The inflammatory& neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis 24, 27-53.
7. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM (2006) Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 26, 9047-9056.
8. Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J (2010) Major depression, cognitive dysfunction and Alzheimer's disease: Is there a link? Eur J Pharmacol 626, 72-82.
9. Cho S, Hu Y (2007) Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp Neurol 203, 274-278.
10. Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, Venkataraman V, Nagele RG (2010) Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 1345, 221-232.
11. Neff F, Wei X, Nolker C, Bacher M, Du Y, Dodel R (2008) Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 7, 501-507.
12. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A 106, 12145-12150.
13. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
14. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56, 33-39.
15. Godau J, Knauel K, Weber K, Brockmann K, Maetzler W, Binder G, Berg D (2011) Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol 68, 925-931.
16. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hornig S, Langkamp M (2011) Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy bodyassociated dementias. J Alzheimers Dis 26, 171-179.
17. Finder VH, Vodopivec I, Nitsch RM, Glockshuber R (2010) The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. J Mol Biol 396, 9-18.
18. Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA (2011) Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Abeta in plasma of patients with Alzheimer's disease. Neurobiol Aging 32, 1379-1387.
19. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE (2005) Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 280, 17458-17463.
20. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Roskam S, Stuer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M (2011) Naturally occurring autoantibodies against betaamyloid: Investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 31, 5847-5854.
21. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, Friedland RP, Ramsland PA, Edmundson AB, Weksler ME, Paul S (2008) Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283, 4714-4722.
22. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K, Elistratova EI, Sherstnev VV, Morozova-Roche LA (2007) Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. J Neuroimmunol 186, 181-192.
23. Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, Henriksen G, Behe M, Dodel R (2009) Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 449, 240-245.
24. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919.
25. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab:Aphase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372.
26. Marques-Deak A, Cizza G, Sternberg E (2005) Brain-immune interactions and disease susceptibility. Mol Psychiatry 10, 239-250.